OBR Daily Commentary - Kidney (Renal Cell) Cancer

forumImage

Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

(BMS) Mar 6, 2018 - Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo ® (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.

H. Jack West, MD (Posted: March 06, 2018)

quotesWith the evidence on immune checkpoint inhibitors in many cancer settings being highly comparable, practical issues like interval between treatments and cost become the leading points of differentiation. An approved four week dosing schedule will lead me to favor this for a larger proportion of my patients moving forward.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

First Opinion: Lives Hang In The Balance As Health Insurers Drag Their Feet On Coverage Appeals

(STAT) Feb 13, 2018 - Health insurers in the United States “keep on giving” when it comes to dishing out outrage to Americans who have already been battered by their denials for coverage.

Winston Wong, PharmD (Posted: February 19, 2018)

quotesI lived through and was part of the payer process for many years. It is not a perfect system. It is a system developed for population health management. Unfortunately, the process for those falling outside of the population is not a smooth process. I venture to say that the time frame referred to here was a couple of years ago when genomic signatures were still up and coming. The mere fact that it was paid for is notable. Unfortunately, dealing with the results is not notable. Hopefully today, the test are more readily paid for and the results are believed.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...